Takeda at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Takeda at ASHG 2026 in Montréal: 1 presentation (1 poster).

OrganizationASHG 2026 Attendance
Takeda
Osaka, Japan
1 presenter
takeda.com|LinkedIn
Public company~49,095 people
Committed to better health for individuals, Takeda in the U.S. markets innovative pharmaceutical treatments.
Won FDA approval for ORZEYFUL, an oral orexin receptor agonist for adult narcolepsy type 1, adding a new neurology drug.
›
Won FDA approval for ORZEYFUL, an oral orexin receptor agonist for adult narcolepsy type 1, adding a new neurology drug.
2026-08 · source
Appointed Julie Kim as president and CEO, a top leadership change that could reshape its strategic priorities.
2026-06 · source
Restructured its executive leadership team and organization, a broad change that may shift priorities across business units.
2026-01 · source
Source: company newsroom
Q1 FY2026 revenue ¥1.22T, down 0.5% at constant FX
›
Guidance: low-single-digit core-revenue decline, 5%-8% operating-profit decline, mid-teens EPS decline this year. · 2026-07-30
“Revenue 1,106,685 1,219,900 113,215 10.2% (0.5)%; Core revenue Low-single digit % decline; Core operating profit 5% to 8% decline; Core EPS Mid-teens % decline”
Source: results release
Currently hiring: 873 open roles
›
Source: careers page
Poster
Wed Oct 21
2:30 pm

Explore the full ASHG 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Montréal. Leave your work email and we’ll be in touch.

Privacy

Download the full ASHG 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Takeda

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction